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REPLY: Is Coronary WedgePressure a Technique to Identify High-Risk
Patients Who May Beneﬁt From Alternative
Treatment in Acute Myocardial Infarction?
Is This The Next Step?We would like to thank Prof. Iancu and colleagues
for their comments about our recent publication (1).
They raise 3 important points:
1. Which patient and procedural factors impact on
microvascular function (MF) after primary angio-
plasty (PPCI)? We have not analyzed thrombus size
and composition, but we agree that this could
provide insights into the mechanisms of MF
observed at the completion of PPCI. MF is multi-
factorial in this situation, reﬂecting a combination
of ischemic injury, prior and procedure-associated
distal embolization, and patient factors such as
age and diabetes. We have recently addressed the
speciﬁc effect of coronary stent implantation on
MF, and identiﬁed that the most important
determinants of change in MF are lesion location,
thrombus burden, implanted stent volume, and
baseline MF (2).
2. Use of coronary wedge pressure (CWP): There are a
number of indices of MF available. The speciﬁc aim
of our study was to compare Doppler and
thermodilution-derived indices. We agree that
ofﬂine analysis is time-consuming, but we do not
believe that this ﬁnding provides only prognosticinformation. We have previously shown that ﬁnal
myocardial salvage is related to both end-of-
procedure MF and how MF changes over the sub-
sequent day, suggesting that identiﬁcation of
patients with impaired MF at the completion of
PPCI could identify an especially high-risk group in
which additional interventions maybe most bene-
ﬁcial (3).
3. Assessment of CWP before coronary stenting: CWP
provides a simple measure, but in patients with
collateral ﬂow especially, it is maybe less reliable
than a number of alternative indices. Ultimately,
however, an enhanced understanding of the coro-
nary microcirculation at the time of PPCI and the
utility of different measures is essential if we are to
achieve better outcomes from reperfusion for all of
our patients.Niket Patel, MBBS, BSc
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Personalized Antiplatelet
TherapyThe Odyssey ContinuesWe read with great interest the RECLOSE 3
(REsponsiveness to CLOpidogrel and Stent Throm-
bosis 3) study reported by Valenti et al. (1) in which
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106the authors investigated the clinical efﬁcacy of
prasugrel in clopidogrel nonresponders undergoing
percutaneous coronary intervention (PCI) with drug-
eluting stents. As stated by the authors, clopidogrel
nonresponse or high on-treatment platelet reactivity
(HTPR) after a clopidogrel loading dose has been
identiﬁed as a major risk factor for recurrent
ischemic events in acute coronary syndrome patients
undergoing PCI. It is associated with an increased risk
of cardiovascular (CV) death, myocardial infarction,
and stent thrombosis (2). Consistent with the results
of this study, a meta-analysis by Aradi et al. (3) sug-
gested that HTPR was associated with a 3.35-fold
increase in CV mortality. This issue is very relevant
because a large majority of patients undergoing PCI
are currently treated with clopidogrel despite its
limitations.
However, the RECLOSE 3 trial has methodological
limitations that distort its conclusion. First, as
stated by the authors, it is a historical cohort com-
parison with the RECLOSE 2 (REsponsiveness to
CLOpidogrel and Stent Thrombosis 2) trial, which
represents the “control” group of clopidogrel non-
responders. However, the RECLOSE 2 trial was
already an interventional trial in which clopidogrel
nonresponders had an increase in their clopidogrel
maintenance dose in order to reach a platelet
reactivity (PR) <70% on an adenosine diphosphate
test. This group of patients therefore cannot repre-
sent a valid clopidogrel nonresponders group. Sec-
ond, the RECLOSE 3 trial population, unlike that of
the RECLOSE 2 trial, included stable patients who
are at low risk of events and in whom HTPR has
limited prognosis implications (4). This could skew
the results despite adjustments, and they should
have been excluded from the analysis.
Third, in the present study, there are 2 limitations
to the antiplatelet therapy protocol proposed. First,
no prasugrel loading dose was used. It is well
demonstrated that most events related to HTPR are
early events, including periprocedural events, and
therefore a prasugrel loading dose should have been
used to optimize PR inhibition (3). In addition,
the duration of dual antiplatelet therapy is not
provided. After publication of the DAPT trial, it could
be postulated that a difference in the duration of
dual antiplatelet therapy between the 2 groups may
have contributed to the observed difference in
outcome (5).
Another major limitation lies in the fact that
bleeding events were not reported. In fact, prasugrel is
associatedwith a signiﬁcant increase inmajor bleeding
events in ACS patients undergoing PCI, which couldoffset its potential beneﬁt on ischemic events.
Balancing ischemic and bleeding events is critical to
improve outcomes in patients undergoing PCI.
Finally, several studies have investigated the
potential of PR monitoring in order to improve the
outcome in patients with HTPR undergoing PCI.
However, although small studies had promising
results, large-scale randomized trials failed to show
any difference in outcome. An adequately designed
and powered trial is still warranted to provide a safe
and efﬁcient alternative to clopidogrel in patients
with HTPR. Selection of patients and of the inter-
vention to overcome HTPR will be critical in this
lasting odyssey.*Laurent Bonello, MD, PhD
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REPLY: Personalized Antiplatelet Therapy:The Odyssey ContinuesWe appreciate the interest of Dr. Bonello and col-
leagues in our paper on the RECLOSE-3 (REspon-
siveness to CLOpidogrel and StEnt Thrombosis 3)
study (1). However, all their comments and criticisms
